Grünenthal USA Inc.
Grünenthal USA has been named one of the 2017 Best Places to Work in New Jersey.
Grünenthal USA Inc.
Partner in Pain Management
Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management.
Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.
Address:
Grünenthal USA, Inc.
360 Mount Kemble Avenue
Morristown, NJ 07960
908-306-0024 (phone)
908-306-1631 (fax)
Treatment of CRPS
Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of CRPS, a debilitating orphan disease
Grünenthal and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease. Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need.
Grünenthal focusses on developing new therapies/medicines for patients. In order to make these therapies/medicines available to patients, Grünenthal is conducting rigorous clinical trials to assess the safety and efficacy of the investigational therapies/medicines, which if proven, will enable the necessary approvals from regulatory authorities. This process will allow patients to have broad access to these medicines. We encourage patients who want access to our investigational therapies/medicines to participate in our clinical trial programs. Given the investigational status of our compounds in clinical development, we currently do not grant expanded access.
